Background: Cervical cancer poses a significant global health challenge for women, with conventional treatments such as surgery, radiotherapy, and chemotherapy often accompanied by side effects and drug resistance. Objective: This review aims to explore the potential of ?-mangostin in cervical cancer treatment, focusing on its anticancer properties. Methods: We conducted a structured literature search of PubMed, Scopus, Web of Science Core Collection, ScienceDirect, and Google Scholar up to December 2025 using combinations of terms related to ?-mangostin and cervical cancer/HPV. Peer-reviewed original studies and relevant reviews were screened for relevance, and findings were synthesized qualitatively without meta-analysis or formal risk-of-bias assessment. Results: ?-Mangostin exhibits multiple anti-cancer properties, including inducing apoptosis in cervical cancer cells, inhibiting proliferation, modulating signaling pathways, targeting HPV oncogenes (E6/E7), and reversing chemotherapy resistance. Conclusions: Findings suggest ?-mangostin holds promise as a complementary therapy for cervical cancer, offering potential benefits including affordability and sustainability. Further research into ?-mangostin may enhance cervical cancer treatment approaches, improve survival rates, and address the rising mortality rates associated with the disease.